Geodon (Ziprasidone): Clinical Overview
Geodon (ziprasidone) is an atypical antipsychotic FDA-approved for schizophrenia, acute bipolar mania, bipolar maintenance (as adjunct), and acute agitation in schizophrenia, but carries a critical QT prolongation risk that requires cardiac screening and contraindication awareness before use. 1
FDA-Approved Indications
Ziprasidone has four specific FDA approvals 1:
- Schizophrenia (oral formulation, adults)
- Acute manic or mixed episodes in bipolar I disorder (oral, monotherapy, adults)
- Maintenance treatment of bipolar I disorder (oral, adjunct to lithium or valproate, adults)
- Acute agitation in schizophrenia (intramuscular formulation, adults)
Dosing Guidelines
Oral Formulation (Schizophrenia/Bipolar Disorder)
Start at 40 mg twice daily with food, then titrate to the effective range of 80-160 mg/day (divided twice daily). 1 The maximum recommended dose is 80 mg twice daily (160 mg/day total). 2, 3
Critical administration requirement: Ziprasidone must be taken with meals (at least 500 calories) to achieve adequate absorption—food increases bioavailability by approximately 2-fold. 4, 2 This is a common pitfall leading to treatment failure.
Intramuscular Formulation (Acute Agitation)
For acute agitation, administer 10-20 mg IM as needed, with maximum 40 mg/day. 1 Specific dosing intervals:
- 10 mg doses: every 2 hours as needed
- 20 mg doses: every 4 hours as needed
The 20 mg IM dose is significantly more effective than 10 mg for rapid agitation control. 5 Class II evidence demonstrates ziprasidone IM 20 mg rapidly reduces agitation symptoms within 15-30 minutes with notably lower extrapyramidal symptoms compared to haloperidol. 5
IM use is limited to 3 consecutive days maximum—transition to oral formulation as soon as clinically appropriate. 1 Do not co-administer IM and oral ziprasidone simultaneously. 1
Reconstitution for IM Use
Add 1.2 mL Sterile Water for Injection to single-dose vial, shake vigorously until dissolved (yields 20 mg/mL). Draw 0.5 mL for 10 mg dose or 1.0 mL for 20 mg dose. Discard unused portion—contains no preservative. 1
Absolute Contraindications
Ziprasidone is contraindicated in the following scenarios 1:
Cardiac Contraindications
- Known QT prolongation (including congenital long QT syndrome)
- Recent acute myocardial infarction
- Uncompensated heart failure
- Concurrent use with other QT-prolonging drugs including: dofetilide, sotalol, quinidine, Class Ia/III antiarrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, moxifloxacin, pentamidine, arsenic trioxide, and others with documented QT prolongation warnings 1
Other Contraindications
- Known hypersensitivity to ziprasidone 1
- Current MAOI use or within 14 days of MAOI discontinuation (including linezolid and IV methylene blue) due to serotonin syndrome risk 1
- Wait at least 3 days after stopping ziprasidone before starting an MAOI 1
Monitoring Requirements
Baseline Assessment (Before Initiating)
- ECG with QTc measurement (mandatory given QT prolongation risk)
- Screen for cardiac history: arrhythmias, recent MI, heart failure
- Electrolytes (potassium, magnesium)—correct abnormalities before starting
- Medication review to identify QT-prolonging drugs
- Blood pressure
Ongoing Monitoring
- QTc interval monitoring during treatment, especially with dose increases or addition of other medications
- Electrolytes periodically, particularly if patient has risk factors for imbalance
- Blood pressure (ziprasidone can cause orthostatic hypotension)
- Weight and metabolic parameters (though ziprasidone is weight-neutral, baseline documentation is prudent) 6, 3
- Extrapyramidal symptoms assessment (though incidence is low)
Key Safety Considerations
QT Prolongation
All six studied antipsychotics prolong QTc at maximum recommended doses, with ziprasidone causing moderate prolongation (less than thioridazine, more than olanzapine), though none exceeded 500 ms in controlled studies. 5 Despite this, avoid ziprasidone in patients with cardiac arrhythmia history or congenital long QT syndrome. 1
Tolerability Profile
Ziprasidone offers advantages over other atypicals 6, 3:
- Weight-neutral (no significant weight gain)
- Low metabolic risk (no hyperlipidemia or hyperglycemia)
- Low extrapyramidal symptoms (significantly lower than haloperidol) 5
- Most common adverse effects: somnolence (14%), nausea (10%), dyspepsia 4, 7
- Early-onset restlessness/akathisia can occur—address proactively to prevent discontinuation 8
Special Populations
- Elderly with dementia-related psychosis: Black box warning—increased mortality risk. Ziprasidone is NOT approved for this population. 1
- Parkinson's disease psychosis: Generally well-tolerated but can occasionally worsen motor symptoms, particularly in dementia with Lewy bodies. Use cautiously. 9
Common Pitfalls to Avoid
- Inadequate food intake with oral doses—leads to subtherapeutic levels and treatment failure
- Underdosing—effective range is typically 120-160 mg/day for schizophrenia, not the starting 80 mg/day 2
- Failing to screen for QT prolongation risk factors before initiation
- Co-prescribing with QT-prolonging medications without recognizing the contraindication
- Prolonged IM use beyond 3 days without transitioning to oral formulation
- Not addressing early restlessness/akathisia, leading to premature discontinuation
Clinical Efficacy Context
Class II evidence demonstrates ziprasidone IM 20 mg is effective for acute agitation with rapid onset (15-30 minutes), equal efficacy to haloperidol plus lorazepam, but with significantly fewer movement disorders and reduced restraint time. 5 For maintenance treatment, ziprasidone shows equivalent efficacy to other atypicals for positive symptoms with particular advantage in its metabolic neutrality. 6, 3